JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.32 -2.94

Buy Sell

Overview

Share price change

24h

Current

Min

1.3

Max

1.38

Key metrics
By Trading Economics
Income	-124K -32M
Sales	-372K 1.4M
EPS	-0.27
Profit margin	-2,364.792
Employees	161
EBITDA	-13M -42M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+45.99% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-13M 162M
Previous open	4.26
Previous close	1.32

News Sentiment

By Acuity

33%

67%

117 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 kwi 2026, 00:00 UTC

Earnings

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24 kwi 2026, 00:00 UTC

Earnings

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23 kwi 2026, 23:47 UTC

Market Talk

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23 kwi 2026, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 kwi 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

23 kwi 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23 kwi 2026, 23:13 UTC

Acquisitions, Mergers, Takeovers

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23 kwi 2026, 22:33 UTC

Earnings

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23 kwi 2026, 22:17 UTC

Earnings

PLS Executed Offtake Agreement With Ronbay

23 kwi 2026, 22:17 UTC

Earnings

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23 kwi 2026, 22:16 UTC

Earnings

PLS Commences Commissioning of Midstream Demonstration Plant

23 kwi 2026, 22:15 UTC

Earnings

PLS Group Reaffirms FY26 Guidance for All Metrics

23 kwi 2026, 22:14 UTC

Earnings

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23 kwi 2026, 22:14 UTC

Earnings

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23 kwi 2026, 22:13 UTC

Earnings

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23 kwi 2026, 22:12 UTC

Earnings

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23 kwi 2026, 22:12 UTC

Earnings

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23 kwi 2026, 22:11 UTC

Earnings

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23 kwi 2026, 22:10 UTC

Earnings

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23 kwi 2026, 22:09 UTC

Earnings

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23 kwi 2026, 22:08 UTC

Earnings

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23 kwi 2026, 22:04 UTC

Earnings

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23 kwi 2026, 21:56 UTC

Market Talk

Earnings

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23 kwi 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23 kwi 2026, 21:27 UTC

Earnings

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23 kwi 2026, 21:25 UTC

Earnings

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23 kwi 2026, 21:24 UTC

Earnings

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23 kwi 2026, 21:24 UTC

Earnings

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23 kwi 2026, 21:21 UTC

Earnings

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23 kwi 2026, 21:21 UTC

Earnings

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

45.99% upside

12 Months Forecast

Average 2 USD 45.99%

High 2 USD

Low 2 USD

Based on 3 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

117 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.